Updates
Clarification w.r.t. news item which appeared in the Bloombergquint.07-02-2018
Clarification sought from Cadila Healthcare Ltd
The Exchange has sought clarification from Cadila Healthcare Ltd on February 07, 2018, with reference to news appeared in www.bloombergquint.com dated February 07, 2018 quoting "U.S. FDA Conducts Surprise Audit At Cadila's Moraiya Plant". The reply is awaited.07-02-2018
Analyst / Investor Meet - Intimation
Pursuant to regulation 30 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, we hereby inform that the Company has planned investor interaction through a conference call on February 8, 2018 at 4:00 p.m., post announcement of unaudited financial results for the quarter / nine months ended on December 31, 2017.31-01-2018
Cadila Healthcare turns focus on vaccines and biosimilars
Analysts expect the two segments to contribute 25% of domestic revenue in 2 years; vaccines contribute less than 1% of revenues at present, while biosimilars account for 4.5% of domestic revenues24-01-2018
Press Release / Media Release
Cadila's Dabhasa API facility successfully completes USFDA inspection19-01-2018
Statement Of Investor Complaint For The Quarter Ended On December 31, 2017
Statement of Investor Complaint for the quarter ended on December 31, 201712-01-2018
Shareholding for the Period Ended December 31, 2017
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here11-01-2018
Board Meeting On 08-02-2018
We hereby inform that the meeting of the Board of Directors of the Company will be held on Thursday, February 8, 2018 to consider apart from other agenda items to approve the unaudited financial results for the quarter / nine months ended on December 31, 2017. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain...10-01-2018
Press Release / Media Release
Zydus receives final approval from the USFDA for Valacyclovir Tablets USP30-12-2017
Press Release / Media Release
Zydus receives final approval from the USFDA for Clomipramine Hydrochloride Capsules USP.29-12-2017